Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief ...

Results of the first-in-human, randomized, double-blind, placebo-controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau ...

For PSP, they are AADvac1, AZP2006, and a drug to be announced. For CBS, no official word, but the drug is likely BIIB080. Industry representatives from 52 companies joined. “That was great to see,” ...